300006 Chongqing Lummy Pharmaceutical
- 2.88
- +0.12+4.35%
Chongqing Lummy Pharmaceutical News
Laimei Pharmaceuticals: Announcement on preparation for asset impairment accrued for the first quarter of 2024
Lamy Pharmaceuticals: Report for the first quarter of 2024
Laimei Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Laimei Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Chongqing Laimei Pharmaceutical Co., Ltd.
Laimei Pharmaceuticals: Announcement on the lawsuit filed by a wholly-owned subsidiary
Laimei Pharmaceuticals: 300006 Laimei Pharmaceuticals Investor Relations Management Information 20240403
Laimei Pharmaceuticals: Guojin Securities's regular on-site inspection report on continued supervision of Laimei Pharmaceuticals
Laimei Pharmaceuticals: Guojin Securities\'s 2023 follow-up report on Laimei Pharmaceuticals
Laimei Pharmaceuticals: Guojin Securities Summary Report on Continued Supervision and Sponsorship of Laimei Pharmaceuticals Issuance of Shares to Specific Targets in 2021
Laimei Pharmaceutical: Announcement on participating companies obtaining approval notices for drug clinical trials
Laimei Pharmaceutical: Announcement on the holding subsidiary obtaining a medical device registration certificate
Laimei Pharmaceuticals: Announcement on holding the 2023 Online Results Briefing
Laimei Pharmaceuticals: Internal Control Verification Report
Laimei Pharmaceuticals: Annual Report 2023
Laimei Pharmaceutical: Announcement of Board Resolutions
Laimei Pharmaceuticals: Internal Control System
Laimei Pharmaceuticals: 2023 Supervisory Committee Work Report
Laimei Pharmaceuticals: Special opinion of the board of directors on the sole director's independence assessment
Laimei Pharmaceuticals: Guojin Securities's inspection opinions on Laimei Pharmaceuticals' 2023 internal control evaluation report
Laimei Pharmaceuticals: 2023 Internal Control Evaluation Report
Analysis
Price Target
No Data
